Pharmaceutical SOE Holding Drives Sustainable Transformation in Subsidiaries
PT Bio Farma, as the parent company of the State-Owned Pharmaceutical Holding, continues to drive transformation and continuous improvement across all subsidiaries and affiliates. This strategic agenda is directed towards strengthening governance, increasing operational discipline, optimising assets, and building healthier and more sustainable business competitiveness.
Transformation within the Bio Farma Group is part of a comprehensive effort to ensure that every business entity possesses a strong foundation that is adaptive to the dynamics of the healthcare industry. This step is expected to create added value for the state and all stakeholders.
One positive development from this agenda can be seen in PT Indofarma Tbk. Through efficiency measures, cost control, strengthened governance, and the optimisation of operational processes, Indofarma continues to implement fundamental improvements in a disciplined and measurable manner.
The President Director of Bio Farma, Shadiq Akasya, stated that the transformation across all Bio Farma Group entities is not only oriented towards short-term performance improvements but also towards building long-term business readiness.
“Bio Farma continues to encourage transformation and continuous improvement across all subsidiaries and affiliates to strengthen governance, operations, and business competitiveness. At Indofarma, improvement steps have shown positive progress through efficiency, cost control, and operational optimisation,” Shadiq said in an official statement on Monday.
Shadiq added that this commitment is part of Bio Farma Group’s efforts to support the strengthening of national health resilience and the contribution of the Indonesian health industry on a global level. According to him, strengthening governance and operational discipline is a vital foundation in facing increasingly complex industry challenges.
Therefore, Bio Farma will continue to oversee transformation steps through increased accountability, portfolio and asset optimisation, strengthening production capabilities, and business development aligned with market needs and national health priorities.
Moving forward, Bio Farma Group will strengthen synergy between entities to build a more integrated, resilient, and competitive healthcare industry ecosystem. This step is expected to support the business sustainability of all group members while expanding the role of the Indonesian pharmaceutical industry on the international stage.